Skip to content

Study · Non-randomized trial · 1996

4 results

Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: a longitudinal study.

Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Rossi S, Gennari C

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA1 Jan 1996Cited by 42 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, lumbar spine BMD changed by 1.99% with salmon calcitonin and calcium versus -2.66% with calcium alone, a significant difference.

    In plain wordsIn osteoporotic women, spine bone density increased with salmon calcitonin and calcium versus a decrease with calcium alone.

    Outcome
    IncreaseLumbar spine BMD
    Study

    n: not reported in source

    Comparator
    Calcium alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU/day, 1 month on and 1 month off · intranasal · 2 yearsAs given in this study (human).

    Measurements

    BMD change
    1.99%
    calcitonin and calcium
    BMD change
    −2.66%
    calcium alone

    Source sentences

    Summary
    In the calcitonin-treated group at the end of the study period BMD had increased by 1.99%, SOS by 0.20%, BUA by 0.88% and Stiffness by 2.12%.
    4 context sentences
    Summary · context
    By contrast in the calcium-treated group all parameters had decreased (BMD, -2.66%; SOS, -0.55%; BUA, -3.30%; Stiffness, -6.0%) by the end of the study period.
    Summary · context
    The differences between groups were significant for BMD, SOS and Stiffness.
    Summary · context
    To compare US with bone mineral density (BMD), we studied 112 osteoporotic women (age range 50-64 years).
    Summary · context
    Seventy-eight of them were treated with salmon calcitonin nasal spray (CT; 200 IU/day, 1 month on and 1 month off) and calcium (500 mg/day); 34 patients were given only calcium.
  2. 02HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, SOS changed by 0.20% with salmon calcitonin and calcium versus -0.55% with calcium alone, a significant difference.

    In plain wordsIn osteoporotic women, bone ultrasound speed increased with salmon calcitonin and calcium versus a decrease with calcium alone.

    Outcome
    IncreaseSpeed of sound
    Study

    n: not reported in source

    Comparator
    Calcium alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU/day, 1 month on and 1 month off · intranasal · 2 yearsAs given in this study (human).

    Measurements

    SOS change
    0.2%
    calcitonin and calcium
    SOS change
    −0.55%
    calcium alone

    Source sentences

    Summary
    In the calcitonin-treated group at the end of the study period BMD had increased by 1.99%, SOS by 0.20%, BUA by 0.88% and Stiffness by 2.12%.
    4 context sentences
    Summary · context
    By contrast in the calcium-treated group all parameters had decreased (BMD, -2.66%; SOS, -0.55%; BUA, -3.30%; Stiffness, -6.0%) by the end of the study period.
    Summary · context
    The differences between groups were significant for BMD, SOS and Stiffness.
    Summary · context
    To compare US with bone mineral density (BMD), we studied 112 osteoporotic women (age range 50-64 years).
    Summary · context
    Seventy-eight of them were treated with salmon calcitonin nasal spray (CT; 200 IU/day, 1 month on and 1 month off) and calcium (500 mg/day); 34 patients were given only calcium.
  3. 03HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, BUA changed by 0.88% with salmon calcitonin and calcium versus -3.30% with calcium alone; BUA is not among the outcomes listed as significantly different between groups.

    In plain wordsIn osteoporotic women, ultrasound attenuation rose with salmon calcitonin and calcium and fell with calcium alone; this difference was not listed as significant.

    Outcome
    IncreaseBroadband ultrasound attenuation
    Study

    n: not reported in source

    Comparator
    Calcium alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU/day, 1 month on and 1 month off · intranasal · 2 yearsAs given in this study (human).

    Measurements

    BUA change
    0.88%
    calcitonin and calcium
    BUA change
    −3.3%
    calcium alone

    Source sentences

    Summary
    In the calcitonin-treated group at the end of the study period BMD had increased by 1.99%, SOS by 0.20%, BUA by 0.88% and Stiffness by 2.12%.
    4 context sentences
    Summary · context
    The differences between groups were significant for BMD, SOS and Stiffness.
    Summary · context
    By contrast in the calcium-treated group all parameters had decreased (BMD, -2.66%; SOS, -0.55%; BUA, -3.30%; Stiffness, -6.0%) by the end of the study period.
    Summary · context
    To compare US with bone mineral density (BMD), we studied 112 osteoporotic women (age range 50-64 years).
    Summary · context
    Seventy-eight of them were treated with salmon calcitonin nasal spray (CT; 200 IU/day, 1 month on and 1 month off) and calcium (500 mg/day); 34 patients were given only calcium.
  4. 04HumanNon-randomized trialEfficacy outcome

    In osteoporotic women, stiffness changed by 2.12% with salmon calcitonin and calcium versus -6.0% with calcium alone, a significant difference.

    In plain wordsIn osteoporotic women, bone stiffness increased with salmon calcitonin and calcium versus a decrease with calcium alone.

    Outcome
    IncreaseStiffness index
    Study

    n: not reported in source

    Comparator
    Calcium alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU/day, 1 month on and 1 month off · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Stiffness change
    2.12%
    calcitonin and calcium
    Stiffness change
    −6%
    calcium alone

    Source sentences

    Summary
    In the calcitonin-treated group at the end of the study period BMD had increased by 1.99%, SOS by 0.20%, BUA by 0.88% and Stiffness by 2.12%.
    4 context sentences
    Summary · context
    By contrast in the calcium-treated group all parameters had decreased (BMD, -2.66%; SOS, -0.55%; BUA, -3.30%; Stiffness, -6.0%) by the end of the study period.
    Summary · context
    The differences between groups were significant for BMD, SOS and Stiffness.
    Summary · context
    To compare US with bone mineral density (BMD), we studied 112 osteoporotic women (age range 50-64 years).
    Summary · context
    Seventy-eight of them were treated with salmon calcitonin nasal spray (CT; 200 IU/day, 1 month on and 1 month off) and calcium (500 mg/day); 34 patients were given only calcium.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.